Axsome Therapeutics Is Maintained at Overweight by Piper Sandler

What happened

Piper Sandler maintained its Overweight rating on Axsome Therapeutics while cutting the price target to $238.00 per share from $258.00, according to Benzinga ratings actions data.

Confirmed

Global impact / market context

A lower price target means Piper Sandler still expects the stock to rise but by less than before, so the firm kept its positive Overweight rating, which means it expects the stock to outperform, while trimming its expected upside.

Analyst inference

This is a single analyst rating update rather than a company announcement. Investors who track analyst views may treat the target cut as a modest reduction in expected upside, while the unchanged Overweight rating signals continued positive expectations for the stock.

Analyst inference

What to watch

1. Piper Sandler's updated price target is $238.00 per share, down from $258.00, while its Overweight rating remains unchanged. Confirmed
2. Watch whether other analysts follow with their own price target changes, since a pattern of cuts would suggest broader reassessment; a single cut alone may not. Proposed
3. Watch Axsome's upcoming company disclosures for signs that revenue, costs, or drug pipeline progress support the analyst's continued Overweight view despite the trimmed target. Analyst inference

Evidence

• Original source link unavailable